<< Read Full Article
<< Read Full Article
CHANGE IN RATINGS
Akamai (AKAM Quote) upgraded at Goldman Sachs to Neutral from Sell following Q1 results that beat expectations. Note that strong international growth offset somewhat weak domestic results, which likely indicate increasing competition. Price target raised to $18.50 from $16.Costco (COST Quote) downgraded at UBS from Buy to Neutral. $52 price target. Valuation call, as the stock is up 25% since early March.
Endo Pharma (ENDP Quote) downgraded at Oppenheimer from Outperform to Perform. Lidoderm may not grow as quickly as expected. Pipeline concerns also remain.
Recent Comments
| Dow Jones | S&P 500 | NASDAQ | 10-Year Note | |
|---|---|---|---|---|
| 10,452.68 | 1,109.24 | 2,185.03 | 33.23 |
Oil *
77.73
|
|
DOWN
18.90
|
UP
0.38
|
UP
9.22
|
UP
0.48
|
10 Yr
3.32%
SPDR Gold
119.18
|
|
-0.18%
|
+0.03%
|
+0.42%
|
+1.47%
|
Data delayed 20 minutes |



Connect with TheStreet